Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants

International Journal of Cancer

Volumn 107, Issue 5, 2003, Pages 757-763

  Miwa, Miyu ^a,b   Tsukahara, Satomi ^a   Ishikawa, Etsuko ^a   Asada, Sakiyo ^a   Imai, Yasuo ^a   Sugimoto, Yoshikazu ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ABC transporter; ABCG2; ABCP; CPT 11; Doxorubicin; Mitoxantrone; Multidrug resistance; MXR; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; ACLARUBICIN; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; COMPLEMENTARY DNA; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ESTRONE; FUMITREMORGIN C; MITOXANTRONE; TOPOTECAN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; MOUSE; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE; CELL MEMBRANE; DNA, COMPLEMENTARY; DRUG RESISTANCE, MULTIPLE; FIBROBLASTS; HUMANS; KINETICS; MICE; MITOXANTRONE; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 0242300543     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11484     Document Type: Article

References (28)

1. Gottesman MM, Hrycyna CA, Schoenlein PV, Germamm UA, Pastan I. Genetic analysis of the multidrug transporter. Ann Rev Genet 1995;29:607-49.
2. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9.
3. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
4. Allikmets R, Schriml L, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-9.
5. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
6. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59:8-13.
7. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, Sugimoto Y. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 2002;97:626-30.
8. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59:4237-41.
9. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999;91: 429-33.
10. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63.
11. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000;113:2011-21.
12. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000;60:831-7.
13. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ ABCP-overexpressing cells. Cancer Res 2001;61:6635-9.
14. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res 2002;62:2294-9.
15. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S. Identification of breast cancer resistant protein/ mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 2001;61: 2827-32.
16. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000;60:47-50.
17. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Estrone and 17β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 2002;93:231-5.
18. Choi KH, Chenm CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988;53: 519-29.
19. Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND, Roninson IB. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185→Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 1990;87:7225-9.
20. Devine SE, Ling V, Melera PW. Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci USA 1992;89:4564-8.
21. Ma JF, Grant G, Melera PW. Mutations in sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal. Mol Pharmacol 1997;51: 922-30.
22. Haimeur A, Deeley RG, Cole SP. Charged amino acids in the sixth transmembrane helix of multidrug resistance protein 1 (MRP1) are critical determinants of transport activity. J Biol Chem 2002;277: 41326-33.
23. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 2003;63:65-72.
24. Loo TW, Clarke DM. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 1993;268:3143-9.
25. Loo TW, Clarke DM. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 1993;268:19965-72.
26. Ito K, Suzuki H, Sugiyama Y. Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2. Mol Pharmacol 2001;59:1077-85.
27. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1: 611-6.
28. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD. Transport of methotrexate, methotrexate polyglutamates and 17β-estradiol 17-(β-D-glucuronide) by ABCG2 (BCRP/MXR): effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54.